EMA publishes overview of medicines recommended in 2022
The European Medicines Agency (EMA) has published its key recommendations for marketing authorisations in 2022 in ‘Human Medicines Highlights 2022’.
Thanks to our guest speaker Prof Asif Ahmed
Those gathered at the annual PharmaMedic Consultancy’s social event on 16 February were treated to an engaging presentation by guest speaker Prof Asif Ahmed.
Medical Technology Strategy launched by UK Government
The UK Government has published its Medical Technology Strategy policy document, designed to ensure that the health and social care system can access safe, effective and innovative medical technologies.
Prof Asif Ahmed guest speaker at PharmaMedic Consultancy event
We are looking forward to PharmaMedic Consultancy’s annual social event this Thursday evening (16 February 2023), featuring guest speaker Prof Asif Ahmed from MirZyme Therapeutics.
UK Government publishes response to MHRA fee consultation
The Government has published its response to the consultation on proposals for changes to the Medicines and Healthcare products Regulatory Agency’s (MHRA) statutory fees.
MHRA announces new international recognition framework for MAs from 2024
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed that the European Commission Decision Reliance Procedure (ECDRP) has been extended to 31 December 2023. After that a new international recognition framework will be instituted, from 1 January 2024.
Join Our Free Breakfast Briefing: Quality Systems in Pharma – Who, What, When?
PharmaMedic is delighted to announce our next virtual event on Thursday 23rd February 2023 at 08am (GMT). In this briefing, we will be discussing the important area of quality systems and their importance in our day-to-day roles. Listen to the discussions then ask any questions you may have. Read on to learn more, and to register your attendance.
UK leads on new regulatory framework for point-of-care medicine manufacturing
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has announced the establishment of a ground-breaking regulatory framework to simplify the manufacture of innovative medicines at the point of care. The UK’s Human Medicines and Clinical Trials legislation will be amended to enable this and brought to parliament later in 2023.
Pharma deals at 41st JP Morgan Healthcare conference
Against a backdrop of challenging circumstances around the globe in 2022, what do the pharma deals announced during the recent JP Morgan Healthcare conference suggest about investor sentiment and the way forward for pharma in 2023?
MHRA ramps up assessment capacity for in-vitro diagnostic devices
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has extended the designation of UL International UK Ltd as an Approved Body.